371 related articles for article (PubMed ID: 16890572)
1. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
2. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
Kilicdag EB; Bagis T; Zeyneloglu HB; Tarim E; Aslan E; Haydardedeoglu B; Erkanli S
Hum Reprod; 2005 Apr; 20(4):894-9. PubMed ID: 15618250
[TBL] [Abstract][Full Text] [Related]
3. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
4. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome.
Spranger J; Möhlig M; Wegewitz U; Ristow M; Pfeiffer AF; Schill T; Schlösser HW; Brabant G; Schöfl C
Clin Endocrinol (Oxf); 2004 Dec; 61(6):738-46. PubMed ID: 15579189
[TBL] [Abstract][Full Text] [Related]
5. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
[TBL] [Abstract][Full Text] [Related]
6. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
[TBL] [Abstract][Full Text] [Related]
7. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A
J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799
[TBL] [Abstract][Full Text] [Related]
8. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome.
Cataldo NA; Abbasi F; McLaughlin TL; Basina M; Fechner PY; Giudice LC; Reaven GM
Hum Reprod; 2006 Jan; 21(1):109-20. PubMed ID: 16155076
[TBL] [Abstract][Full Text] [Related]
9. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
10. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome.
Pawelczyk L; Spaczynski RZ; Banaszewska B; Duleba AJ
Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):209-13. PubMed ID: 15063962
[TBL] [Abstract][Full Text] [Related]
11. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Baillargeon JP; Jakubowicz DJ; Iuorno MJ; Jakubowicz S; Nestler JE
Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
[TBL] [Abstract][Full Text] [Related]
12. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Piperi C; Kalofoutis A; Creatsas G
Clin Endocrinol (Oxf); 2005 Jan; 62(1):37-43. PubMed ID: 15638868
[TBL] [Abstract][Full Text] [Related]
14. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Clin Endocrinol Metab; 2005 Jan; 90(1):60-5. PubMed ID: 15483106
[TBL] [Abstract][Full Text] [Related]
15. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Kriplani A; Agarwal N
J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
[TBL] [Abstract][Full Text] [Related]
16. Effects of pioglitazone on beta-cell function in metabolic syndrome patients with impaired glucose tolerance.
Jin J; Yu Y; Yu H; Wang C; Zhang X
Diabetes Res Clin Pract; 2006 Dec; 74(3):233-41. PubMed ID: 16764964
[TBL] [Abstract][Full Text] [Related]
17. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262
[TBL] [Abstract][Full Text] [Related]
18. The association of bone mineral density with insulin resistance in patients with polycystic ovary syndrome.
Noyan V; Yucel A; Sagsoz N
Eur J Obstet Gynecol Reprod Biol; 2004 Aug; 115(2):200-5. PubMed ID: 15262356
[TBL] [Abstract][Full Text] [Related]
19. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.
Maciel GA; Soares Júnior JM; Alves da Motta EL; Abi Haidar M; de Lima GR; Baracat EC
Fertil Steril; 2004 Feb; 81(2):355-60. PubMed ID: 14967373
[TBL] [Abstract][Full Text] [Related]
20. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A
J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
